Frequently Asked Questions

What is the primary goal of AAV downstream process development?

The objective is to maximize the recovery of potent, fully packaged viral vectors while efficiently removing process-related impurities such as host cell proteins, DNA, and empty or partially filled capsids.

Why is the full-to-empty capsid ratio a focus for AAV vectors?

This ratio directly impacts vector potency and the safety profile. Empty capsids provide no therapeutic benefit but can contribute to the total vector quantity administered and potentially increase immunogenicity, making their removal a key objective for minimizing clinical risk.

How does AAV serotype influence the purification strategy?

Different AAV serotypes, including AAV8, possess unique isoelectric points and surface charge characteristics. These properties demand tailored chromatography methods, including specific resin selection and buffer conditions, to achieve effective separation and high-purity yields.

Additional Insights

Achieving a high concentration of fully packaged capsids is a primary objective in the process development of advanced therapeutics. For complex biologics like AAV vectors, particularly serotypes such as AAV8, standard platform purification methods often fail to deliver the requisite purity and potency needed for IND-enabling toxicology studies. Applying proven experience in vector process development accelerates these next-generation therapies by resolving specific manufacturing bottlenecks.

The challenge extends beyond simple yield. It involves the selective separation of therapeutically active, full capsids from a complex mixture containing empty capsids and other process-related impurities. These non-functional particles can increase the total vector quantity required for efficacy, a factor with direct implications for the safety profile of the final product.

Preclinical safety evaluations have identified potential toxicities associated with systemic AAV administration at high vector quantities (PMID: 38327046). A robust downstream process that significantly enriches for full capsids is a direct strategy to mitigate this risk. By reducing the amount of inactive viral material administered, programs can potentially lower the total vector needed to achieve a therapeutic effect.

Our process development for AAV8 and other viral vectors focuses on targeted refinements to established purification workflows. This data-driven approach is tailored to the specific physicochemical properties of the target serotype.

• Chromatography Optimization: We utilize platform affinity resins and ion-exchange chromatography steps that exploit the subtle surface charge differences between full and empty capsids.
• Buffer and Elution Tuning: Systematic screening of pH, conductivity, and buffer additives is performed to identify conditions that maximize the resolution and recovery of the target vector.
• Analytical Integration: High-resolution analytical methods, including AUC and ddPCR, are integrated directly into the development workflow to provide immediate feedback on vector quality at each stage of purification.

This methodical refinement of downstream processing is fundamental to supplying high-quality vector for pivotal studies. It directly supports the collective track record of our scientific leadership, a team that achieved a 100% successful IND rate since 2019 prior to the 2024 launch of Franklin Biolabs, enabling programs to meet their 18-24 month timelines to IND.